Home | Breaking Out | AI powered stock trade ideas | Bullish Engulfing | Market Signals | New Green Signal Stocks | Recent Red Arrow Top Signals | Recent Green Arrow Bottom Signals | Near Term Bottom Signals | Green Stocks with Most Upside to Analyst Target Price | New Long Term Green AI Signals | Big Tech Stocks | ETF Sector SPDRs | Solar Stocks | Chip Stocks | Airline Stocks | Social Media Stocks | Oil Stocks| Discount Store Stocks | Entertainment Stocks | EV Stocks | Restaurant Stocks | Heavy Equipment Stocks | Aerospace Stocks | Home Builders | Bank Stock Signals | Cruise Ship Stock Signals | Mining Stocks | Free AI Portfolio Analyzer | How to Read and Trade AI Powered Stock Charts| Stock Charts AI top 50 Stocks

Recently Featured Stock Charts
86% AI Stock Prediction Accuracy
Enter Stock Symbol to View AI powered Stock Chart


All Chart Prices Delayed at least 15 minutes

Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.

Stock Charts AI Power Rank: 9.4
Power Rank trending -> UP

Last Price: 890.11 - Change: 6.23 - Change %: 0.7048
06/24/2024 16:09:00 EST

Eli Lilly and Company (LLY)

Industry: Drug Manufacturers - General

Price Support Resistance

In the past 20 trading days, LLY has been trading in a range between $891.46 and $807.43 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.

LLY is trading below resistance at $891.46, about 0% to the upside. There is support at $772.86 -13% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.

Upside / Downside Potential

Eli Lilly and Company $LLY entered a Green zone 34 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $603.57, a potential down side of -32.19% from the recent price of 890.11. The stock is trading 1.72% (potential upside) below its 52 week high of $905.45 and 106.46 % (potential downside) above its 52 week low of $431.12 - based on the recent price.

Company Summary

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.

LLY Website


Lilly Declares Third-Quarter 2024 Dividend
INDIANAPOLIS , June 24, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on Sept.
Source: PRNewsWire
Mon, 24 Jun 2024 11:30:00 -0400
Sentiment: Neutral
Why a Pair of Eli Lilly Clinical Trials Sent ResMed Stock Tumbling
Shares of medical device maker ResMed (RMD) are tumbling in intraday trading Monday as markets react to a pair of Phase 3 clinical trials from drugmaker Eli Lilly (LLY) released Friday that could have an impact on ResMed's future business.
Source: Investopedia
Mon, 24 Jun 2024 11:26:15 -0400
Sentiment: Negative
Medical-device makers ResMed and Inspire slump after Lilly's Zepbound trial shows benefits for sleep apnea
Shares of medical-device makers ResMed Inc. and Inspire Medical Systems Inc. tumbled on Monday after Eli Lilly & Co. said it has applied for regulatory approval of its weight-loss drug Zepbound to include treatment of sleep apnea.
Source: Market Watch
Mon, 24 Jun 2024 11:26:00 -0400
Sentiment: Negative
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Source: Zacks Investment Research
Mon, 24 Jun 2024 10:05:35 -0400
Sentiment: Positive
Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again
ResMed stock and Inspire Medical Systems stock tumbled Monday after Eli Lilly said its weight-loss drug reduced sleep apnea events.
Source: Investors Business Daily
Mon, 24 Jun 2024 09:23:57 -0400
Sentiment: Negative
Instituions Institution %: 83.771
Last QTR Institution change: -3058740

Insiders %: 0.164
Insiders Purchases last QTR: 0
Insiders Sales last QTR: 957859
Insiders Net last QTR: -957859

Analyst Ratings
Target Price: 603.57
Overall Rating: 4.2857
Strong Buys (5): 16
Buys (4): 5
Holds (3): 6
Sells (2): 1
Strong Sells (1): 0

52 Week Hi: 905.45
52 Week Low: 431.1198
Beta: 0.363
50 Day MA: 797.314
200 Day MA: 683.1523

Earnings / Revenue Trends
Qtr Earnings Growth YOY: 0.664
Qtr Revenue Growth YOY: 0.26
Forward PE: 60.241
Trailing PE: 130.7063

Benefits of StockChartsAI.com System:

  • Get a Daily List of Stocks Starting New Trends
  • Upload Your Stocks to Quickly See and Track Signals
  • Easy to Understand AI Stock Signals
  • Analysis of Historical Signal Trend Analysis for each stock
  • Search/View AI Stock Signals of Russel 1000 Stocks
  • Easy to Understand AI Stock Signals
  • And MUCH MUCH more!


Stock Analyzed Each Night


Easily Upload Track Your Stocks


See Lists of Stocks Starting New Trends

The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.